DELIVERING MORE EFFICIENT TRIAL EXECUTION NO MATTER THE STUDY SIZE

Whether it’s a start-up of five employees trying to manage resources or an emerging biopharma seeking quick implementation of integrated data solutions for accelerated growth, Medidata understands the unique challenges facing mid-market organizations. Our unified data platform and service offering combine the industry’s largest clinical business intelligence repository with user-friendly design, enabling faster study set-up and enhanced success rates. As a premier mid-market partner, we offer more than EDC — we offer end-to-end solutions that scale with your business.

500,000+ EMBRACED SITE RELATIONSHIPS

1,000+ EMERGING SPONSOR RELATIONSHIPS

100+ CRO & PARTNER RELATIONSHIPS

To learn more, please visit mdsol.com

NORTH AMERICA

PhaseBio

Clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for rare diseases.

CHALLENGES

• Limited number of affected patients
• Limited site availability

SOLUTION

• Medidata Rave

BOTTOM LINE

• Rave’s flexible and intuitive design allows scalability to accommodate the growth of PhaseBio’s operations
• Having all clinical data on one platform reduces the stress of merging data sets that would otherwise require manual effort of the internal team

—ERIK PIRHOLM, CHIEF BUSINESS OFFICER

Cancer Research UK

World’s largest cancer charity dedicated to saving lives through research.

CHALLENGES

• Increasingly complex regulatory requirements

SOLUTION

• Edge Quality with SOP implemented in a 6-week timeframe

BOTTOM LINE

• Consolidated documentation environment enables streamlined author-review-approval process
• Greater compliance confidence and inspection readiness
• 62% faster implementation compared to other vendors

—ALAN FARK, CLINICAL RESEARCH ADVISOR

EUROPE

Zosano Pharma

Clinical-stage biopharmaceutical company focused on rapid systemic therapeutics’ administration.

CHALLENGES

• Randomizing trial subjects

SOLUTION

• Integration of Rave RTSM with Rave EDC enabled seamless monitoring

BOTTOM LINE

• Intuitive user interface led to reduced training time, faster access to data
• Product development cycle time shorter than expected
• Faster study start-up

—THOMAS RAY, DIRECTOR OF CLINICAL OPERATIONS

INDEPENDENT

Onconova

Phase III biopharmaceutical company focused on discovery and development of novel small molecule cancer drug candidates.

CHALLENGES

• Difficulty screening patients due to unpredictable eligibility criteria for rare indication and qualification of studies

SOLUTION

• Initial selection of Rave EDC and Rave Coder
• Based on success of platform and company growth, Rave RTSM and Edge Targeted SDV introduced

BOTTOM LINE

• Platform offers flexible control over study build and design, allowing Onconova to explore a variety of different models based on available resources and costs
• Reduced costs of contracting third-party builders
• Standardized study build delivered consistent results and reduced trial start-up time

—PATRICK ZBYSZEWSKI, DIRECTOR OF CLINICAL DATA MANAGEMENT

500,000+

1,000+

100+

-established site relationships

-emerging sponsor relationships

-cro & partner relationships

To learn more, please visit mdsol.com

DELIVERING MORE EFFICIENT TRIAL EXECUTION NO MATTER THE STUDY SIZE

Whether it’s a start-up of five employees trying to manage resources or an emerging biopharma seeking quick implementation of integrated data solutions for accelerated growth, Medidata understands the unique challenges facing mid-market organizations. Our unified data platform and service offering combine the industry’s largest clinical business intelligence repository with user-friendly design, enabling faster study set-up and enhanced success rates. As a premier mid-market partner, we offer more than EDC — we offer end-to-end solutions that scale with your business.

500,000+ EMBRACED SITE RELATIONSHIPS

1,000+ EMERGING SPONSOR RELATIONSHIPS

100+ CRO & PARTNER RELATIONSHIPS

To learn more, please visit mdsol.com

NORTH AMERICA

PhaseBio

Clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for rare diseases.

CHALLENGES

• Limited number of affected patients
• Limited site availability

SOLUTION

• Medidata Rave

BOTTOM LINE

• Rave’s flexible and intuitive design allows scalability to accommodate the growth of PhaseBio’s operations
• Having all clinical data on one platform reduces the stress of merging data sets that would otherwise require manual effort of the internal team

—ERIK PIRHOLM, CHIEF BUSINESS OFFICER

Cancer Research UK

World’s largest cancer charity dedicated to saving lives through research.

CHALLENGES

• Increasingly complex regulatory requirements

SOLUTION

• Edge Quality with SOP implemented in a 6-week timeframe

BOTTOM LINE

• Consolidated documentation environment enables streamlined author-review-approval process
• Greater compliance confidence and inspection readiness
• 62% faster implementation compared to other vendors

—ALAN FARK, CLINICAL RESEARCH ADVISOR

EUROPE

Zosano Pharma

Clinical-stage biopharmaceutical company focused on rapid systemic therapeutics’ administration.

CHALLENGES

• Randomizing trial subjects

SOLUTION

• Integration of Rave RTSM with Rave EDC enabled seamless monitoring

BOTTOM LINE

• Intuitive user interface led to reduced training time, faster access to data
• Product development cycle time shorter than expected
• Faster study start-up

—THOMAS RAY, DIRECTOR OF CLINICAL OPERATIONS

INDEPENDENT

Onconova

Phase III biopharmaceutical company focused on discovery and development of novel small molecule cancer drug candidates.

CHALLENGES

• Difficulty screening patients due to unpredictable eligibility criteria for rare indication and qualification of studies

SOLUTION

• Initial selection of Rave EDC and Rave Coder
• Based on success of platform and company growth, Rave RTSM and Edge Targeted SDV introduced

BOTTOM LINE

• Platform offers flexible control over study build and design, allowing Onconova to explore a variety of different models based on available resources and costs
• Reduced costs of contracting third-party builders
• Standardized study build delivered consistent results and reduced trial start-up time

—PATRICK ZBYSZEWSKI, DIRECTOR OF CLINICAL DATA MANAGEMENT

500,000+

1,000+

100+

-established site relationships

-emerging sponsor relationships

-cro & partner relationships

To learn more, please visit mdsol.com

DELIVERING MORE EFFICIENT TRIAL EXECUTION NO MATTER THE STUDY SIZE

Whether it’s a start-up of five employees trying to manage resources or an emerging biopharma seeking quick implementation of integrated data solutions for accelerated growth, Medidata understands the unique challenges facing mid-market organizations. Our unified data platform and service offering combine the industry’s largest clinical business intelligence repository with user-friendly design, enabling faster study set-up and enhanced success rates. As a premier mid-market partner, we offer more than EDC — we offer end-to-end solutions that scale with your business.

500,000+ EMBRACED SITE RELATIONSHIPS

1,000+ EMERGING SPONSOR RELATIONSHIPS

100+ CRO & PARTNER RELATIONSHIPS

To learn more, please visit mdsol.com

NORTH AMERICA

PhaseBio

Clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for rare diseases.

CHALLENGES

• Limited number of affected patients
• Limited site availability

SOLUTION

• Medidata Rave

BOTTOM LINE

• Rave’s flexible and intuitive design allows scalability to accommodate the growth of PhaseBio’s operations
• Having all clinical data on one platform reduces the stress of merging data sets that would otherwise require manual effort of the internal team

—ERIK PIRHOLM, CHIEF BUSINESS OFFICER

Cancer Research UK

World’s largest cancer charity dedicated to saving lives through research.

CHALLENGES

• Increasingly complex regulatory requirements

SOLUTION

• Edge Quality with SOP implemented in a 6-week timeframe

BOTTOM LINE

• Consolidated documentation environment enables streamlined author-review-approval process
• Greater compliance confidence and inspection readiness
• 62% faster implementation compared to other vendors

—ALAN FARK, CLINICAL RESEARCH ADVISOR

EUROPE

Zosano Pharma

Clinical-stage biopharmaceutical company focused on rapid systemic therapeutics’ administration.

CHALLENGES

• Randomizing trial subjects

SOLUTION

• Integration of Rave RTSM with Rave EDC enabled seamless monitoring

BOTTOM LINE

• Intuitive user interface led to reduced training time, faster access to data
• Product development cycle time shorter than expected
• Faster study start-up

—THOMAS RAY, DIRECTOR OF CLINICAL OPERATIONS

INDEPENDENT

Onconova

Phase III biopharmaceutical company focused on discovery and development of novel small molecule cancer drug candidates.

CHALLENGES

• Difficulty screening patients due to unpredictable eligibility criteria for rare indication and qualification of studies

SOLUTION

• Initial selection of Rave EDC and Rave Coder
• Based on success of platform and company growth, Rave RTSM and Edge Targeted SDV introduced

BOTTOM LINE

• Platform offers flexible control over study build and design, allowing Onconova to explore a variety of different models based on available resources and costs
• Reduced costs of contracting third-party builders
• Standardized study build delivered consistent results and reduced trial start-up time

—PATRICK ZBYSZEWSKI, DIRECTOR OF CLINICAL DATA MANAGEMENT

500,000+

1,000+

100+

-established site relationships

-emerging sponsor relationships

-cro & partner relationships

To learn more, please visit mdsol.com